Literature DB >> 20162668

Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer.

Inti Zlobec1, Michal Kovac, Priska Erzberger, Francesca Molinari, Michel P Bihl, Alexander Rufle, Anja Foerster, Milo Frattini, Luigi Terracciano, Karl Heinimann, Alessandro Lugli.   

Abstract

Confounding effects of specific KRAS gene alterations on colorectal cancer (CRC) prognosis stratified by microsatellite instability (MSI) and BRAF(V600E) have not yet been investigated. The aim of our study was to evaluate the combined effects of MSI, BRAF(V600E) and specific KRAS mutation (GlyAsp; G12D, GlyAsp, G13D; GlyVal; G12V) on prognosis in 404 sporadic and 94 hereditary CRC patients. MSI status was determined according to the Bethesda guidelines. Mutational status of KRAS and BRAF(V600E) was assessed by direct DNA sequencing. In sporadic CRC, KRAS G12D mutations had a negative prognostic effect compared to G13D and wild-type cancers (p = 0.038). With MSI, specific KRAS and BRAF(V600E) mutations, 3 distinct prognostic subgroups were observed in univariate (p = 0.006) and multivariable (p = 0.051) analysis: patients with (i) KRAS mutation G12D, G12V or BRAF(V600E) mutation, (ii) KRAS/BRAF(V600E) wild-type or KRAS G13D mutations in MSS/MSI-L and (iii) MSI-H and KRAS G13D mutations. Moreover, none of the sporadic MSI-H or hereditary patients with KRAS G13 mutations had a fatal outcome. Specific KRAS mutation is an informative prognostic factor in both sporadic and hereditary CRC and applied in an algorithm with BRAF(V600E) and MSI may identify sporadic CRC patients with poor clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20162668     DOI: 10.1002/ijc.25265

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  34 in total

Review 1.  Colorectal cancer molecular biology moves into clinical practice.

Authors:  Colin C Pritchard; William M Grady
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).

Authors:  Harry H Yoon; David Tougeron; Qian Shi; Steven R Alberts; Michelle R Mahoney; Garth D Nelson; Suresh G Nair; Stephen N Thibodeau; Richard M Goldberg; Daniel J Sargent; Frank A Sinicrope
Journal:  Clin Cancer Res       Date:  2014-03-31       Impact factor: 12.531

Review 3.  Molecular alterations and biomarkers in colorectal cancer.

Authors:  William M Grady; Colin C Pritchard
Journal:  Toxicol Pathol       Date:  2013-10-31       Impact factor: 1.902

4.  Tumor TP53 expression status, body mass index and prognosis in colorectal cancer.

Authors:  Teppei Morikawa; Aya Kuchiba; Xiaoyun Liao; Yu Imamura; Mai Yamauchi; Zhi Rong Qian; Reiko Nishihara; Kaori Sato; Jeffrey A Meyerhardt; Charles S Fuchs; Shuji Ogino
Journal:  Int J Cancer       Date:  2011-11-19       Impact factor: 7.396

5.  Neuroendocrine and squamous colonic composite carcinoma: case report with molecular analysis.

Authors:  Sabrina C Wentz; Cindy Vnencak-Jones; William V Chopp
Journal:  World J Gastroenterol       Date:  2011-11-14       Impact factor: 5.742

6.  Sessile serrated adenoma shares similar genetic and epigenetic features with microsatellite unstable colon cancer in a location-dependent manner.

Authors:  Takafumi Maeda; Koichi Suzuki; Kazutomo Togashi; Mitsuhiro Nokubi; Masaaki Saito; Shingo Tsujinaka; Hidenori Kamiyama; Fumio Konishi
Journal:  Exp Ther Med       Date:  2011-04-05       Impact factor: 2.447

7.  Cathepsin B expression and survival in colon cancer: implications for molecular detection of neoplasia.

Authors:  Andrew T Chan; Yoshifumi Baba; Kaori Shima; Katsuhiko Nosho; Daniel C Chung; Kenneth E Hung; Umar Mahmood; Karen Madden; Kirtland Poss; Audrey Ranieri; Daniel Shue; Raju Kucherlapati; Charles S Fuchs; Shuji Ogino
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-09-10       Impact factor: 4.254

Review 8.  KRAS mutation testing in metastatic colorectal cancer.

Authors:  Cong Tan; Xiang Du
Journal:  World J Gastroenterol       Date:  2012-10-07       Impact factor: 5.742

9.  An appraisal of lymph node ratio in colon and rectal cancer: not one size fits all.

Authors:  M Medani; Niall Kelly; George Samaha; G Duff; Vourneen Healy; Elizabeth Mulcahy; Eoghan Condon; David Waldron; Jean Saunders; J Calvin Coffey
Journal:  Int J Colorectal Dis       Date:  2013-05-29       Impact factor: 2.571

10.  Clinical utility of KRAS and BRAF mutations in a cohort of patients with colorectal neoplasms submitted for microsatellite instability testing.

Authors:  Allison M Cushman-Vokoun; Daniel G Stover; Zhiguo Zhao; Elizabeth A Koehler; Jordan D Berlin; Cindy L Vnencak-Jones
Journal:  Clin Colorectal Cancer       Date:  2013-06-14       Impact factor: 4.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.